InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,960.80
(
0.34%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.01
(
-0.48%
)
Bitcoin
57,694.96
(
1.74%
)
Post# of 144814
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

PINKribbon

Send PM Follow Ignore
Followers 5
Posts 1919
Boards Moderated 1
Alias Born 07/04/2017

PINKribbon

Re: None

Thursday, 10/04/2018 11:30:34 AM

Thursday, October 04, 2018 11:30:34 AM

Post# of 144814

The "integration site information" from this study was another requirement requested by the FDA. The site of integration was to be defined and included in PharmaCyte's Investigational New Drug Application (IND) before the start of the clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).



If I'm correct in my research, there may be just one last study to report.

And that would be an analysis of the P450-2B1's enzyme(s) integration site itself.

Again, if I'm correct, they will need to identify and explain to the FDA the "reaction set up", or the cause and effect of the enzyme(s) relative to cell proliferation.

Just my guess.


Go Team PharmaCyte!!!
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent PMCB News
More PMCB News
InvestorsHub NewsWire

Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM

Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM

EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM

BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM

NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM

Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM

Start posting your company's news
Only $200 per official company press release!